Ziccum CEO Analyst video interview: Q2, 2024 highlights

Watch Ziccum CEO Ann Gidner in a comprehensive interview in Swedish with analyst Jonathan Furelid on the highlights of Ziccum’s Q2 2024 report and the company’s current and coming status.

CEO Ann Gidner provides investors with updates and insights on further mRNA/LNP milestones, including the recently disclosed significant mRNA activity increase with LaminarPace, the status of Ziccum’s current partner projects including the newly signed ReCode Therapeutics deal, the growing industry-wide interest for Ziccum and the progress in solidifying Ziccum’s intellectual property protection.

You may watch the interview here: https://youtu.be/6ttsdxZh6UM